Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 4;118(18):e2104740118.
doi: 10.1073/pnas.2104740118.

CD317 puts the brakes on dendritic cell trafficking to the CNS

Sarah E Barnes  1 , May H Han  2
Affiliations

CD317 puts the brakes on dendritic cell trafficking to the CNS

Sarah E Barnes et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Fig. 1.
Fig. 1.
CD317 blockade ameliorates EAE. Early in EAE pathology, a subset of circulating CD11c+ cells up-regulates CD88. CD317 up-regulation on these cells is associated with trafficking to the perivascular spaces of the CNS. A similar subset of CD11c+CD88+CD317+ microglia-like cells is observed in the cerebrospinal fluid of patients with MS. Treatment with a monoclonal antibody targeting CD317 reduces trafficking of CD11c+CD88+ cells to the CNS and abrogates EAE pathology.
See this image and copyright information in PMC

Comment on

  • doi: 10.1073/pnas.2014492118

References

    1. Filippi M., et al. ., Multiple sclerosis. Nat. Rev. Dis. Primers 4, 43 (2018). - PubMed
    1. Manouchehri N., et al. ., CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 118, e2014492118 (2021). - PMC - PubMed
    1. Rommer P. S., et al. ., Immunological aspects of approved MS therapeutics. Front. Immunol. 10, 1564 (2019). - PMC - PubMed
    1. Lehmann-Horn K., Kronsbein H. C., Weber M. S., Targeting B cells in the treatment of multiple sclerosis: Recent advances and remaining challenges. Ther. Adv. Neurol. Disord. 6, 161–173 (2013). - PMC - PubMed
    1. Chisari C. G., et al. ., Rituximab for the treatment of multiple sclerosis: A review. J. Neurol., 10.1007/s00415-020-10362-z (2021). - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources